Atjaunināt sīkdatņu piekrišanu

Prostate Cancer from a Nuclear Oncology Perspective: A Personal Journey [Hardback]

  • Formāts: Hardback, 233 pages, height x width: 235x155 mm, 74 Illustrations, color; 18 Illustrations, black and white; XV, 233 p. 92 illus., 74 illus. in color., 1 Hardback
  • Izdošanas datums: 14-May-2025
  • Izdevniecība: Springer International Publishing AG
  • ISBN-10: 3031903366
  • ISBN-13: 9783031903366
Citas grāmatas par šo tēmu:
  • Hardback
  • Cena: 118,31 €*
  • * ši ir gala cena, t.i., netiek piemērotas nekādas papildus atlaides
  • Standarta cena: 139,19 €
  • Ietaupiet 15%
  • Grāmatu piegādes laiks ir 3-4 nedēļas, ja grāmata ir uz vietas izdevniecības noliktavā. Ja izdevējam nepieciešams publicēt jaunu tirāžu, grāmatas piegāde var aizkavēties.
  • Daudzums:
  • Ielikt grozā
  • Piegādes laiks - 4-6 nedēļas
  • Pievienot vēlmju sarakstam
Prostate Cancer from a Nuclear Oncology Perspective: A Personal JourneyPalielināt
  • Formāts: Hardback, 233 pages, height x width: 235x155 mm, 74 Illustrations, color; 18 Illustrations, black and white; XV, 233 p. 92 illus., 74 illus. in color., 1 Hardback
  • Izdošanas datums: 14-May-2025
  • Izdevniecība: Springer International Publishing AG
  • ISBN-10: 3031903366
  • ISBN-13: 9783031903366
Citas grāmatas par šo tēmu:
Permanent link: https://www.kriso.lv/db/9783031903366.html
Keywords:
This book provides a comprehensive review of innovative diagnostic methods for prostate cancer, with a particular emphasis on the development of PET radiopharmaceuticals. The author has had the privilege to introduce several tracers into clinical routine practice, including Na18F, 18F-FCH, 18F-FACBC, 68Ga-PSMA11, 18F-PSMA-1007, and 18F-DCFPyL. Thus, indications in various prostate cancer subgroups are discussed in detail, weighing the pros and cons in clinical practice. In the authors“ practice radiation therapy has been more important and surgical applications; therefore, PET based dose planning is presented in detail. Furthermore, the author has closely followed the development of radiopharmaceutical treatments, particularly in the context of bone pain palliation using radiopharmaceuticals, such as 89SrCl2, 186ReHEDP, 153SmEDTMP, 117mSnDTPA, and 223RaCl2, and targeted treatments (177Lu-PSMSA-617, 177Lu-PSMA-I&T and 225Ac-PSMA).



Thanks to his experience, the author facilitated the set-up of targeted treatments in various countries: Baltic and Nordic countries, elsewhere in Europe, North America (Canada), and Africa (e.g. Ghana). The author's involvement in promoting therapy tourism to Finland further highlights his breadth of knowledge and practical experience.



This book offers valuable insights into the evolving landscape of diagnostic methods and radiopharmaceutical treatments for prostate cancer. With the author's extensive experience and contributions to the field, readers can gain a comprehensive understanding of these advancements and their implications in clinical practice.
1. Introduction prostate cancer from the point of view of the author
and the history of imaging.-
2. Integrated summary of research on
radioiodinated estramustine phosphate and estramustine binding protein
antibody in prostate cancer treatment.-
3. Summary of Diagnostic Accuracy of
18F-Fluorocholine PET/CT in Prostate Cancer Staging.-
4. Overview of 18F-NaF
PET/CT Imaging.-
5. 18F-Fluciclovine (18F-FACBC) Positron Emission Tomography
in Prostate Cancer.-
6. PSMA-PET in prostate cancer.-
7. 18F-FLT PET/CT in
Prostate Adenocarcinoma .-
8. 18F-FDHT-PET Imaging in the Management of
Hormone-Dependent  Prostate Cancer.-
9. Immunoscintigraphy and
radioimmunotherapy of prostate cancer incuding own personal journey -anti-PAP
and anti-PSMA antibodies.-
10. Briefly about radiation therapy.-
11. PET/CT
for Radiation Therapy Planning of Prostate Cancer .-
12. Brief overview of
prostate cancer treatment modalities.-
13. Radium-223 Dichloride (Ra-223) for
the Treatment of Metastatic Castration-resistant Prostate Cancer.-
14.
Lu-177-PSMA treatment in prostate cancer.-
15. Clinical Experience in
225Ac-PSMA.-
16. Multicenter trials prostate radioligand therapy (PRLT) in
castration resistant cancer.-
17. Meta-analyses and systematic reviews (own
experience) in prostate cancer.-
18. Own history of cancer suspicions.-
19.
Public appearance because of nuclear oncology (pictorial essay).- . Appendix
- ISUP and PI-RADS classifications.
Prof Kairemo graduated with a MSc (Eng) degree from Helsinki University of Technology (Chemical Engineering) in 1980 before undertaking medical training (MD (86), PhD (93)) at the University of Helsinki, Finland. He undertook specialist training in Clinical Chemistry (94), Nuclear Medicine (96), Health Care Administration (02) and Pharmaceutical Medicine (06) at Helsinki University Central Hospital. He had a post-doctoral research fellowship at Memorial Sloan-Kettering Cancer Center in 1989-93 in New York. Besides homeland Finland he is licensed medical specialist in Norway (1998), Sweden (2001) and Estonia (2010).



Prof Kairemo has held posts as Professor in Clinical Chemistry at the Norwegian University of Science and Technology (1998-9), Professor in Nuclear Medicine at Uppsala University Hospital in Sweden (2001-5) and as Head of the Nuclear Medicine Division, Department of Oncology at Helsinki University Central Hospital (2004-9). In 2009-2018, he has been the Chief of Nuclear Medicine and Molecular Radiotherapy (Theragnostics) at the Docrates Cancer Center, in Helsinki. Since 2015 he has acted as Visiting Professor in the Nuclear Medicine Department of The University of Texas MD Anderson Cancer Center, in Houston, TX; last visits in 2019, 2022 and 2023.



Prof Kairemo has also held posts in industry, as Medical Director of CTT Cancer Targeting Technologies Oy (2001-6), Medical Director of Imanext Oy (2006-8) and Clinical Director at Advanced Accelerator Applications SA in 2009 (now Novartis Co.).



Besides a few patents prof Kairemo has published more than 250 original publications in peer-reviewed journals. He received the Lifetime Achievement Award from the World Association of Radiopharmaceutical and Molecular Therapy in 2012 and was President of the 7th International Conference on Radiopharmaceutical Therapy held in November 2012 in Levi in Finnish Lapland. In 2014, Dr Kairemo hosted ISORBE Symposium and Workshop Cell Labelling and Cell Therapies in Helsinki. He also organized the 14th International Symposium on Radiopharmaceutical Therapy (WARMTH) in November 2018 in Helsinki. He was elected in 2022 as the new President of the WARMTH for 2024-2025.